Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,048 Mln
P/E Ratio
--
P/B Ratio
5
Industry P/E
--
Debt to Equity
0.12
ROE
-0.73 %
ROCE
-61.68 %
Div. Yield
0 %
Book Value
1.52
EPS
-0.7
CFO
$-695.78 Mln
EBITDA
$-1,044.08 Mln
Net Profit
$-999.51 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Wave Life Sciences (WVE)
| -40.66 | -14.85 | -39.04 | 57.51 | 48.98 | -4.91 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Wave Life Sciences (WVE)
| -27.86 | 122.93 | -60.10 | -1.81 | -80.93 | 19.65 | 34.23 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines... multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. Address: Marina One East Tower, Singapore, Singapore, 018936 Read more
President, CEO & Director
Dr. Paul B. Bolno M.B.A., M.D.
President, CEO & Director
Dr. Paul B. Bolno M.B.A., M.D.
Headquarters
Singapore
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Wave Life Sciences Ltd (WVE) stood at $ 352 Mln as on 31-Dec-24
The share price of Wave Life Sciences Ltd (WVE) is $7.34 (NASDAQ) as of 29-Apr-2025 16:01 EDT. Wave Life Sciences Ltd (WVE) has given a return of 48.98% in the last 3 years.
Wave Life Sciences Ltd (WVE) has a market capitalisation of $ 1,048 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Wave Life Sciences Ltd (WVE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Wave Life Sciences Ltd (WVE) and enter the required number of quantities and click on buy to purchase the shares of Wave Life Sciences Ltd (WVE).
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. Address: Marina One East Tower, Singapore, Singapore, 018936
The CEO & director of Dr. Paul B. Bolno M.B.A., M.D.. is Wave Life Sciences Ltd (WVE), and CFO & Sr. VP is Dr. Paul B. Bolno M.B.A., M.D..
There is no promoter pledging in Wave Life Sciences Ltd (WVE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Wave Life Sciences Ltd. (WVE) | Ratios |
|---|---|
|
Return on equity(%)
|
-75.49
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-89.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Wave Life Sciences Ltd (WVE) was $0 Mln.
$0.51
(
